Detalles de la búsqueda
1.
A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.
Acta Oncol
; 55(3): 341-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26449266
2.
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
J Oral Maxillofac Surg
; 71(9): 1532-40, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23642545
3.
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Clin Cancer Res
; 12(4): 1229-36, 2006 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16489078
4.
Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma.
J Invest Dermatol
; 126(4): 849-54, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16410782
5.
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.
Oncoimmunology
; 5(4): e1100788, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27141381
6.
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
Radiother Oncol
; 77(2): 143-7, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16216360
7.
Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy.
Melanoma Res
; 15(5): 409-16, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16179868
8.
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Eur Urol
; 68(3): 516-22, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25533417
9.
Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer.
Int J Radiat Oncol Biol Phys
; 59(2): 436-44, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15145160
10.
Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.
Eur J Cancer
; 50(3): 553-62, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24215846
11.
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
Clin Cancer Res
; 16(21): 5312-9, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20959407
12.
Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Cancer
; 106(5): 1130-9, 2006 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16456816
13.
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
J Clin Oncol
; 24(5): 798-804, 2006 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-16391295
14.
Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Cancer Immunol Immunother
; 53(8): 729-39, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15088127
Resultados
1 -
14
de 14
1
Próxima >
>>